EW - Edwards Lifesciences Corporation
| Previous Close | 138.56 |
| Open | 138.79 |
| Bid | 138.61 x 100 |
| Ask | 138.76 x 200 |
| Day's Range | 138.21 - 139.43 |
| 52 Week Range | 97.63 - 143.22 |
| Volume | 256,371 |
| Avg. Volume | 1,352,858 |
| Market Cap | 29.096B |
| Beta | 0.68 |
| PE Ratio (TTM) | 51.19 |
| EPS (TTM) | 2.70 |
| Earnings Date | Apr 24, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 145.20 |
- Zacks•1 hour ago
Edwards Lifesciences' (EW) THVT Likely to Drive Q1 Earnings
Edwards Lifesciences (EW) is expected to gain from strength in THVT on continued therapy adoption across all geographies in Q1.
- Investor's Business Daily•18 hours ago
Aortic Stenosis, And The Race To Catch Edwards Lifesciences' Heart Valves
Edwards Lifesciences, Medtronic, Boston Scientific and Abbott Laboratories are duking it out for a share of the fast-growing heart-valve replacement market.
- Zacks•2 days ago
4 MedTech Stocks to Keep in Good Books This Earnings Season
Considering the ageing population, changing market dynamics, upbeat consumer sentiment and increased business investments, the Medical-Device sector appears to be in pink of health.
- Zacks•7 days ago
Here's Why You Should Steer Clear of AmerisourceBergen Now
AmerisourceBergen (ABC) continues to witness headwinds due to slowdown in hepatitis C revenues and conversion of branded drugs to the lower price generics.
- Zacks•9 days ago
Will Edwards' (EW) Growth in All Lines Drive Q1 Earnings?
Edwards Lifesciences (EW) is expected to gain from strength in all the business segments and solid performance across all geographies.
- Zacks•9 days ago
Varian Medical (VAR) Launches Velocity 4.0, Shares Rise
The introduction of Velocity 4.0 is in line with Varian Medical's (VAR) strategy to target the radiation-dosimetry market. The platform will help patients with liver malignancies.
- PR Newswire•10 days ago
Edwards Lifesciences To Host Earnings Conference Call On April 24, 2018
IRVINE, Calif. , April 10, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, ...
- Market Realist•10 days ago
Abbott’s Stock Price Momentum Continues: What’s Ahead?
On April 5, 2018, Abbott Laboratories (ABT) ended the trading day at $59.86 per share. The stock registered a rise of ~0.67% in its stock price compared to its previous day’s close. For more details, read Abbott Laboratories Traded at a 52-Week High after Posting Strong 4Q17 Results.
Market Realist•10 days agoAnalysts’ Latest Recommendations and Target Prices for Abbott
Abbott Laboratories (ABT) showed an impressive performance in 2017 despite a challenging macroeconomic environment and big-ticket acquisitions. The company reported strong 2017 results on January 24, 2018, and it has secured a number of product approvals and reimbursement approvals since then, strengthening its market position.
- Market Realist•11 days ago
MitraClip Drives Growth, Gets Reimbursement Approval in Japan
On March 19, 2018, Abbott Laboratories (ABT) announced that it had received reimbursement approval for its MitraClip device in Japan. MitraClip is a minimally invasive procedure for patients suffering from MR (mitral regurgitation) who are at high risk of open surgery.
- Market Realist•14 days ago
What’s behind Edwards Lifesciences’ Latest Valuation
Recent Developments at Edwards Lifesciences
- Zacks•15 days ago
Medtronic to Grow on Strong Fundamentals, High Costs a Woe
Medtronic's (MDT) latest restructuring Enterprise Excellence plan intends to achieve $3 billion of annual growth run rate savings by the end of fiscal 2022
- Zacks•15 days ago
Align Unveils Vivera Retainers for Deep Bite Correction
Align (ALGN) hopes to taste greater clinical success in the orthodontic space with Vivera Retainers' integration into Precision Bite Ramps, which are part of the company's Invisalign G5.
- Market Realist•15 days ago
A Look at Edwards Lifesciences’ Acumen Hypotension Software
Recent Developments at Edwards Lifesciences
Market Realist•15 days agoEdwards Lifesciences Gets CE Mark Approval for Its Centera Valve
Recent Developments at Edwards Lifesciences
- Market Realist•15 days ago
Edwards Lifesciences Delays European Launch of Sapien 3 Ultra
Recent Developments at Edwards Lifesciences
- Market Realist•16 days ago
What’s Driving Boston Scientific Stock Upward
Boston Scientific Acquires Securus Medical
- Market Realist•16 days ago
Wall Street’s Recommendations for BSX Stock
Boston Scientific Acquires Securus Medical
Market Realist•16 days agoBoston Scientific Announces Acquisition of Securus Medical
Boston Scientific Acquires Securus MedicalBoston Scientific’s Securus Medical acquisition
- Market Realist•16 days ago
Edwards Lifesciences and Boston Scientific: Patent Dispute Update
On March 23, 2018, Edwards Lifesciences (EW) announced that it won its dispute with Boston Scientific (BSX) over US Patent 8992608. The USPTO (US Patent and Trademark Office) decided in favor of Edwards in an inter partes review filed by Boston Scientific against Edwards for its TAVR (transcatheter aortic valve replacement) technology, finding all the related claims against Edwards to be invalid.
- Market Realist•16 days ago
What’s behind Edwards Lifesciences’ Stock Rise?
Recent Developments at Edwards Lifesciences
Market Realist•16 days agoAnalysts Give Edwards Lifesciences Mostly ‘Buy’ Ratings
Recent Developments at Edwards LifesciencesAnalysts’ recommendations
- Zacks•17 days ago
FDA Nod for Abiomed Impella CP with SmartAssist Widens Suite
Abiomed (ABMD) continues with the slew of developments to boost its flagship, Impella product line.
- Zacks•18 days ago
Walgreens Boots' Retail Business Solid Amid Several Concerns
Walgreens Boots (WBA) progresses with consistent sales rise in the Retail Pharmacy International business. Moreover, the stock grows on strategic alliances.
- Zacks•18 days ago
Haemonetics' Plasma Tool Enhancement Gets 510(K) Clearance
Haemonetics (HAE) witnesses steady growth in Plasma franchise, led by strong end-market demand for plasma-derived biopharmaceuticals.
